Our governance.
The Board of GARDP determines GARDP’s strategic goals and ensures that management works diligently and efficiently to meet these goals.
It receives guidance from the Scientific Advisory Committee, while GARDP staff carry out day-to-day operations, focusing on the core business of developing and delivering treatments for drug-resistant infections.
GARDP Board
The Board meets twice per year and serves as the ultimate decision-making body of our organization. It establishes GARDP policies and principles, and appoints the Board Chair, Vice-Chair, and Treasurer, as well as GARDP’s Executive Director. GARDP is working to ensure organic growth of the Board and taking steps to increase the representation of key partners from low- and middle-income countries.
Glenda Gray
Chair
SAMCR & Wits University
Bernard Pécoul
Vice-chair
Independent
Stanislas Zuin
Board Treasurer
Independent
Gregg Alton
Board member
Independent
Chieko Ikeda
Board member
Japanese Red Cross
Veronika von Messling
Board member
Federal Ministry of Research, Technology and Space
Board of GARDP
Glenda Gray
Professor Glenda Gray is the Chief Scientific Officer at the South African Medical Research Council (SAMRC) and a Distinguished Professor and senior advisor to the Infectious Disease and Oncology Research Institute, Faculty of Health Sciences, Wits University, Johannesburg. She is also a Professor in the Vaccine and Infectious Disease Division at the Fred Hutch Cancer Research Center in Seattle. Prof Gray leads the BRILLIANT Consortium, which aims to develop an HIV vaccine pipeline emanating from the African continent. She is the former President and CEO of the SAMRC, a position she held for two five-year terms. Prof Gray also co-founded and is a non-Executive Director of the Perinatal HIV Research Unit (PHRU), in Soweto, South Africa. An A-Rated researcher, Prof Gray has been the recipient of multiple grants from the National Institutes of Health (NIH) and is internationally known for her research in HIV vaccines and interventions to prevent mother-to-child transmission of HIV.
Prof Gray’s research has focused on COVID-19 vaccine studies, paediatric treatment trials, large-scale HIV clinical trials, and TB, influenza and HPV vaccine studies in infants, children, adolescents and adults. She is co-Principal Investigator of the NIH-funded HIV Vaccine Trials Network (HVTN) and directs its programme in Africa. Prof Gray was Vice-Chair of the GARDP Board. She was also the Chair of South Africa’s Research Committee on COVID-19.
Prof Gray’s accolades over the years include the Outstanding Africa Scientist Award from the European and Developing Countries Clinical Trials Partnership, and South Africa’s highest honour, the Order of Mapungubwe, granted by the President of South Africa. She also received the N’Galy Mann Lectureship award, alongside Professor James McIntyre, at the Conference on Retroviruses and Opportunistic Infections (CROI). In recognition of her work in HIV, Forbes named Prof Gray as one of Africa’s 50 Most Powerful Women in 2020 while she was listed by The Times as one of the 100 Most Influential People in the World in 2017.
Prof Gray serves on the CEPI scientific advisory committee, has been a member of the WHO-Strategic Advisory Group for TB and has served on the World Health Organization/UNAIDS Vaccine Advisory Board, as well as the Data and Safety Monitoring Board for two vaccine studies in Africa. She chaired the standing committee on health for the Academy of Science and was appointed by South Africa’s Minister of Science, Innovation and Higher Education to the National Research Foundation and the University of Cape Town’s Council, after serving as a Member of the Wits University Council. As a member of the National Academy of Medicine, of the National Academies in the US, she served on the Board for Global Health.
Board of GARDP
Bernard Pécoul
Dr Bernard Pécoul led the Drugs for Neglected Diseases initiative (DNDi) from its foundation in 2003 until 2022. Under his leadership, DNDi – a not-for-profit research and development organization – expanded to include hundreds of public and private partners on five continents. During his tenure, DNDi delivered 12 new treatments for six deadly diseases, including malaria, leishmaniasis, sleeping sickness and Chagas disease. Dr Pécoul’s work has helped to demonstrate that an alternative, collaborative model of research & development can deliver to meet the needs of neglected patients. During his time at DNDi, the organization established five research platforms that are driving scientific and medical progress in countries and communities most affected by neglected diseases. Dr Pécoul is a lifelong advocate for better access to medicines.
In 2016, DNDi, together with the World Health Organization, created GARDP to address the growing threat of antimicrobial resistance. GARDP became an independent entity in 2018.
Dr Pécoul is a recipient of the Prince Mahidol Award in the field of public health (2020) and the American Society of Tropical Medicine and Hygiene Clara Southmayd Ludlow Medal (2022).
He began his career as a Médecins Sans Frontières (MSF) doctor in 1983, working in Africa, Latin America and Asia. He later served as Executive Director of MSF France from 1991 to 1998 and as Director of the MSF Access to Essential Medicines Campaign from 1998 to 2003. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specializing in epidemiology. After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws degree by the University of Dundee, UK. Dr Pécoul was a board member of GARDP from 2019 to 2024. He is a member of the Board of the European Clinical Research Alliance on Infectious Diseases (ECRAID) and a former founding board member of UNITAID’s Medicines Patent Pool.
Board of GARDP
Stanislas Zuin
Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies.
He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit.
He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).
Board of GARDP
Gregg Alton
Mr. Alton spent more than 20 years at Gilead Sciences, where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton currently serves on the United States Presidential Advisory Council on HIV/AIDS, is a member of the board of directors of Novavax Inc., Brii Biosciences, Corcept Therapeutics, Enochian Biosciences, and several non-profit organizations, including The Hepatitis Fund, ETR and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.
Board of GARDP
Chieko Ikeda
Dr Chieko Ikeda is Executive Officer of Blood Service Board of Management at the Japanese Red Cross Society. For over 30 years, she has been engaged in public health, including as Director General of the Bureau of International Health Cooperation at Japan’s National Center for Global Health and Medicine (2021-2023) and as Senior Assistant Minister for Global Health at Japan’s Ministry of Health, Labour and Welfare (2017-2019). She also previously led the technology transfer programme at the Western Pacific Regional Office of the World Health Organization (1999-2000) and worked at the UNAIDS Southeast Asia and Pacific regional office (2000-2003). Dr Ikeda has a bachelor’s degree in medicine from Tsukuba University and master’s degrees in public health and science from the Harvard School of Public Health.
Board of GARDP
Veronika von Messling
Prof. Dr. Veronika von Messling, is Director-General for Life Sciences at the German Federal Ministry of Research, Technology and Space. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.
After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.
Observers of the Board
Observers of the Board include, but are not limited to: a representative from the World Health Organization (a co-founder of GARDP); a representative from DNDi (a co-founder of GARDP); the Chair of the Scientific Advisory Committee. Observers liaise between the Board and the groups they represent. They offer counsel and participate in all board meetings but do not have voting rights.
Herman Goossens
Board observer
University of Antwerp
Luis Pizarro
Board Observer
DNDi
Pending identification
Board observer
World Health Organization
Board Observers
Herman Goossens
Herman Goossens is Emeritus Professor of Microbiology at the University of Antwerp since October 2022. Herman contributed to close to 800 peer-reviewed scientific papers in some of the best journals such as Lancet, New England Journal of Medicine and Nature. He received several honours and awards, such as the Methusalem Award of the Flemish government and the Award for Excellence of the European Society for Medical Microbiology and Infectious Diseases. Herman is the initiator of the Belgian Antibiotic Policy Co-ordination Committee (BAPCOC), of the European Surveillance of Antimicrobial Consumption (ESAC-Net), and of the annual European Antibiotic Awareness Day.
With his translational research, Herman seeks to enhance the standard of healthcare, public health and professional standards. His vision is to build a sustainable infrastructure for clinical research on infectious diseases in Europe. Herman’s coordination of a great number of international research projects has been fundamental in the fight against antimicrobial resistance and pandemic infectious diseases.
Board Observers
Luis Pizarro
Dr Luis Pizarro has led the Drugs for Neglected Diseases initiative (DNDi) since September 2022.
Dr Pizarro is a medical doctor and global health leader. He also serves as founder and member of the Global Health 2030 think tank, as scientific advisor for Global Health at Sciences Po Paris, and as board member of Sidaction. Having led medical projects for several years in West Africa, he became the first CEO of Solthis, from 2007 to 2019, successfully developing the international health and solidarity organization to become one of the leaders in health in West and Central Africa. In 2020, Dr Pizarro joined Unitaid’s leadership team during the COVID crisis to lead the international organization’s HIV portfolio and related access programmes.
Born in Chile, and trained as a medical doctor at the University of Paris, he also holds a masters’ degree in Political Sciences from Sciences Po and an executive health MBA from a joint programme of EHESP School of Public Health, the London School of Economics, and the ESCP European Management School.
Board Observers
Pending identification
The Scientific Advisory Committee
The Scientific Advisory Committee (SAC) is made up of scientists with expertise in various disciplines within infectious diseases and microbiology. SAC members advise and make recommendations to the GARDP Board to carry out the organization’s scientific objectives. They also assess GARDP’s R&D strategy and projects, and provide guidance as well as medical and scientific expertise for GARDP’s programmes. SAC Ex-Officio Members represent external organizations at SAC meetings.
Herman Goossens
Chair
University of Antwerp
Greg Basarab
Committee member
Independent
Heike Brötz-Oesterhelt
Committee member
University of Tübingen
Ana Cristina Gales
Committee member
Universidade Federal de São Paulo
Valeria Gigante
Ex-officio member
World Health Organization
Roy Jamieson
Committee member
OkerPharma Consultancy AB
Thomas P. Lodise
Committee member
Albany College of Pharmacy and Health Sciences (ACPHS)
Sumati Nambiar
Committee member
Johnson and Johnson
Loice Achieng Ombajo
Committee member
University of Nairobi
Pinyo Rattanaumpawan
Committee member
Mahidol University
Tanu Singhal
Committee member
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute
Teodora Wi
Committee member
World Health Organization
SAC
Herman Goossens
Herman Goossens is Emeritus Professor of Microbiology at the University of Antwerp since October 2022. Herman contributed to close to 800 peer-reviewed scientific papers in some of the best journals such as Lancet, New England Journal of Medicine and Nature. He received several honours and awards, such as the Methusalem Award of the Flemish government and the Award for Excellence of the European Society for Medical Microbiology and Infectious Diseases. Herman is the initiator of the Belgian Antibiotic Policy Co-ordination Committee (BAPCOC), of the European Surveillance of Antimicrobial Consumption (ESAC-Net), and of the annual European Antibiotic Awareness Day.
With his translational research, Herman seeks to enhance the standard of healthcare, public health and professional standards. His vision is to build a sustainable infrastructure for clinical research on infectious diseases in Europe. Herman’s coordination of a great number of international research projects has been fundamental in the fight against antimicrobial resistance and pandemic infectious diseases.
SAC
Greg Basarab
Greg Basarab works as an independent consultant with a variety of entities engaged in Infectious Disease drug discovery research. Previously, he sat on the Executive Committee (EXCO) of the Holistic Drug Discovery & Development Centre (H3D) of the University of Cape Town, South Africa, to co-direct business and funding activities while managing the scientific staff that includes Medicinal Chemistry, Computer-Aided Drug Design (CADD); Pharmacology (ADME and in vivo PK); and Biosciences (AMR, tuberculosis, and malaria parasitology). Greg had also worked at AstraZeneca where he led multidisciplinary discovery project teams directed at the discovery and design of novel mode-of-action antibacterials with three entering human clinical trials. One project he led produced Zoliflodacin, a novel mode-of-action antibacterial for the treatment of gonorrhea having completed Phase 3 trial and now awaiting FDA approval. A second project involved development of the enabling process to the newly FDA approved Durlobactam, a second generation DABCO-class β-lactamase inhibitor that, in combination with Sulbactam, is targeted for the treatment of Acinetobacter baumannii infections. He also worked at Dupont where he led projects within three departments of the DuPont Corporation: Central Research & Development, Biochemicals and Agricultural Products working in the antifungal arena and in automated chemical synthesis. Greg was trained as a synthetic organic chemist having earned a PhD at MIT and a BS at Penn State University, both degrees in Chemistry. He an author of over 70 peer-reviewed publications and co-inventor of over 40 patent applications, 22 of which have been granted by the US Patent Office.
SAC
Heike Brötz-Oesterhelt
Heike Brötz-Oesterhelt is a microbiologist having worked in antibacterial drug discovery in the academic and pharmaceutical industry setting for more than 25 years.
After a diploma in biology and her PhD in Microbiology, she joined the Anti-Infectives Department of Bayer HealthCare and later co-founded the anti-infective biotech company AiCuris. In 2010, she returned to academia as a professor for Pharmaceutical Biology at the University of Düsseldorf, and since 2014 she is professor for Microbiology at the University of Tübingen heading the Department of Microbial Bioactive Compounds.
Heike is co-speaker of the Cluster of Excellence “Controlling Microbes to Fight Infection” as well as deputy speaker of the partner site Tübingen within the German Center of Infection Research (DZIF). Her scientific focus is unraveling the molecular mechanisms of new antibiotic agents and operation modes of novel antibiotic targets.
SAC
Ana Cristina Gales
Ana Cristina Gales, MD, PhD, is a Professor in the Division of Infectious Diseases at the Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-UNIFESP), where she also serves as Director of the Laboratory Alerta in São Paulo, Brazil. She received her medical degree from the Faculdade de Medicina do ABC (FMABC) in 1991 and completed her residency in internal medicine and infectious diseases at EPM-UNIFESP between 1992 and 1995. Dr. Gales earned her PhD in Health Sciences from EPM-UNIFESP in 2001, complemented by a research fellowship in medical microbiology at the Department of Pathology, University of Iowa, Iowa City, USA (1998–2000).
Dr. Gales’ research focuses on the molecular epidemiology of multidrug-resistant bacteria and the evaluation of the in vitro activity of novel antimicrobial agents. She has authored more than 300 peer-reviewed publications, which have received over 18,300 citations as of January 2026.
She is a full member of the Technical Chamber on Microbial Resistance in Health Services (CATREM), advising the Brazilian Health Regulatory Agency (Anvisa) on antimicrobial resistance (AMR) standards and control measures in healthcare settings. She also serves as Deputy Coordinator of the Antimicrobial Resistance Institute of São Paulo (ARIES), a recently established initiative aimed at advancing AMR research and strategies in Brazil. Since June 2025, Dr. Gales has served as a Health Area Manager at the São Paulo Research Foundation (FAPESP).
Dr. Gales has contributed to numerous global surveillance programs monitoring antimicrobial resistance trends and phenotypes among clinically significant pathogens. She served as Chair of the Brazilian Committee on Antimicrobial Susceptibility Testing (BrCAST) from 2017 to 2018 and currently serves on the editorial boards of The Brazilian Journal of Infectious Diseases and the Journal of Global Antimicrobial Resistance.
SAC
Valeria Gigante
Dr. Valeria Gigante is a Clinical Pharmacologist with 18 years of experience in research and development (R&D), medicines regulation, and public health policy at global, regional, and national levels. She joined the World Health Organization (WHO) in 2017, focusing on pharmaceutical norms and standards for quality, safety and efficacy. Since 2021, she has led WHO’s R&D and innovation team coordinating efforts to address antimicrobial resistance (AMR). In this role, she oversees prioritization exercises to define strategic areas that, through partnerships, support the development of novel antimicrobials—including paediatric formulations—alongside vaccines and diagnostics. Prior to WHO, Dr. Gigante served as a Pharmaceutical Regulator at the European Medicines Agency (EMA) and as a Clinical Assessor for marketing authorization and scientific advice at the Italian Medicines Agency (AIFA).
She holds a Master’s degree in pharmacy with a specialization in microbiology and infection prevention and control, and earned a Ph.D. in Pharmacology and Toxicology from the University of Rome “La Sapienza,” focusing on pharmacological interventions for multidrug-resistant tuberculosis. Additionally, she completed executive education in healthcare innovation at INSEAD and in global health diplomacy at the Geneva Graduate Institute.
Dr. Gigante represents WHO on the Scientific Advisory Committees of GARDP, the AMR Action Fund, and the Global R&D Hub. She actively contributes to several WHO expert groups, including those on monoclonal antibodies, inclusion of pregnant and lactating women in clinical trials, and the diagnostics task force. Committed to advancing science and innovation, she also serves on the Programme Committee for the ESCMID/GAMRIC Conference on Innovation in R&D.
SAC
Roy Jamieson
Roy is a Pharmacist by training graduating from Nottingham University, UK and now based in Sweden. During his early formative career, he gained experience in pharmaceutical development and manufacturing.
He is an experienced Pharma Industry & Regulatory CMC professional having spent time as a quality assessor at MHRA and with over 25 years in large pharma organisations leading numerous small molecule projects from FTiH through Marketing Authorisation and launch.
As an Independent Consultant he has worked with many small companies as well as collaborating with consultancy firms & a UK based pharmaceutical development service company. He is currently supporting the South African Agency (SAHPRA) as a Quality/CMC reviewer supporting their generic backlog programme and has recently started supporting a Swedish based rare disease Biotech company with their biologics portfolio.
Roy has successfully led 4 major global submissions through Phase 3 to marketing authorisation approval. His key area of regulatory scientific expertise and interest centres on biopharmaceutics aspects of solid oral dosage forms of small molecules and the bridge between quality performance and the pharmacokinetic profile linked to safety and efficacy.
SAC
Thomas P. Lodise
Thomas P. Lodise, PharmD, PhD, is Professor at Albany College of Pharmacy and Health Sciences (ACPHS) and an Infectious Diseases Clinical Pharmacy Specialist at the Stratton VA Medical Center in Albany, New York. He holds the distinction of being the inaugural Rudolph and Dorothy Blythe Endowed Research Chair for Pharmacy and Pharmaceutical Sciences at ACPHS. With more than 23 years of experience in infectious diseases (ID) clinical care and research, Dr. Lodise is internationally recognized for his expertise in antimicrobial resistance (AMR), pharmacokinetics/pharmacodynamics (PK/PD), health economics and outcomes research, comparative effectiveness, and advanced clinical trial design.
He currently serves as PK Scientific Lead for the NIH-funded Antibacterial Resistance Leadership Group (ARLG) and as a member of the Executive Committee for the United States Committee on Antimicrobial Susceptibility Testing (USCAST). He is also Scientific Editor for the Journal of Antimicrobial Chemotherapy and Pharmacotherapy and serves on several journal editorial boards.
Dr. Lodise’s research program integrates pharmacometrics, outcomes research, and epidemiology to improve care for patients with AMR infections. His work has advanced personalized treatment strategies that enhance outcomes, minimize drug toxicity, limit resistance, and improve healthcare delivery. Two practice-changing contributions from his research include extended β-lactam infusions and vancomycin AUC-guided dosing and monitoring.
He has authored more than 250 peer-reviewed articles, many of which are considered seminal in ID pharmacotherapy. With an H-index of 65 and over 19,200 citations, Dr. Lodise is ranked among the top two percent of cited scientists globally and in the top one percent within his three primary fields: Microbiology, Pharmacology & Pharmacy, and Biomedical Research.
SAC
Sumati Nambiar
Dr Nambiar is board-certified in paediatrics and paediatric infectious diseases and is a Fellow of the American Academy of Pediatrics. She has over 20 years of experience in anti-infective product development and regulatory science. She worked at the US Food and Drug Administration for 22 years in various capacities, including eight years as Director, Division of Anti-Infectives.
Prior to moving to the US, Dr Nambiar trained and worked as a paediatrician in India. She completed her residency in paediatrics, including a year as Chief Resident at Inova Fairfax Hospital for Children in Virginia, and a fellowship in paediatric infectious diseases at Children’s National Hospital in Washington, DC. She earned a master’s degree in Public Health, Epidemiology track, from the George Washington University School of Public Health.
SAC
Loice Achieng Ombajo
Loice Achieng Ombajo, is an Infectious Disease specialist, Senior lecturer at the University of Nairobi Department of Medicine and co-director of the Center for Epidemiological Modelling and Analysis (CEMA). She is a member of the WHO Expert Advisory Panel on drug evaluation and chairs the WHO Technical Advisory Group on antibiotic AWaRe and chairs multiple antimicrobial stewardship committees and the National technical working group on AMS.
Loice leads work in AMR surveillance, antimicrobial stewardship and in HIV where she is currently leading large clinical trials. Her focus is on optimising the clinical management of infectious diseases and supporting data driven clinical and public health policy decisions.
SAC
Pinyo Rattanaumpawan
Professor Pinyo Rattanaumpawan, MD, MSCE, PhD, is a Professor of Medicine at Division of Infectious Diseases and Tropical Medicine, the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, and serves as Executive Director of the Clinical Trial Unit. She leads the Antimicrobial Stewardship Program at Siriraj Hospital and holds key roles nationally and internationally, including with the Infectious Disease Association of Thailand, the National AMR Working Group, the National List of Essential Medicines (Infectious Disease Subcommittee), and the WHO Technical Advisory Group on AWARE.
Her research focuses on antimicrobial resistance (AMR) and antimicrobial stewardship (AMS), with over 20 clinical trials and nearly 100 international peer-reviewed publications. Her work has been recognized by the 2026 SHEA International Ambassador Program, the 2019 SHEA William Jarvis Award, and the 2017 Institut Mérieux Young Investigator Award.
SAC
Tanu Singhal
Dr Tanu Singhal is a Consultant in Pediatric Infectious Diseases at Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India. She has trained in Pediatrics at All India Institute of Medical Sciences New Delhi and in Tropical Medicine and International Health at the London School of Medicine and International Health, London, UK. She has been practising clinical infectious diseases for the past 25 years at Mumbai. Her chief areas of expertise include drug resistant bacterial infections, tuberculosis and invasive fungal infections. She was a member of the technical advisory group to National Tuberculosis Elimination Program from 2015-2025. She is a board member of the Fungal Infection Study Forum since 2012. She is also a member of the Governing Council of the Clinical Infectious Diseases Society of India. She regularly collaborates with the Indian Council of Medical Research for developing clinical guidelines and in matters of antimicrobial resistance. She has been awarded the prestigious Dr IC Verma Excellence award for Young Paediatricians in 2022. She was the National Convener of the Indian Academy of Pediatrics Committee of Immunization between 2007-2008.
She has 115 publications in PUBMED indexed journals with 12000 citations in google scholar with an h index of 35 and i-10 index of 63. She has authored three books namely on immunization, rational antimicrobial therapy in children and on COVID-19.
SAC
Teodora Wi
Dr. Teodora Elvira C. Wi is an internationally recognized global health leader with over 30 years of experience in the prevention, control, and management of sexually transmitted infections (STIs) and HIV across Africa, Asia, and Latin America. She currently serves as a Consultant in the HIV, STI, and Hepatitis Programmes of the World Health Organization (WHO) Western Pacific Region, providing strategic and technical support to strengthen country responses and regional initiatives.
Previously, Dr. Wi served as the Lead for Sexually Transmitted Infections in the Department of Global HIV, Hepatitis and STI Programmes at WHO Headquarters in Geneva, Switzerland. In this role, she led the development and global implementation of WHO’s STI guidelines, coordinated the Global Action Plan to address antimicrobial resistance (AMR) in STIs, and provided technical leadership to WHO regional and country offices in advancing the Global Health Sector Strategy on STIs. Her leadership contributed significantly to strengthening STI surveillance systems, shaping global health policies, and guiding the design and implementation of evidence-based research and programmes.
Prior to her tenure at WHO Headquarters, Dr. Wi served as Medical Officer and later Acting Team Leader for HIV/AIDS and STIs at the WHO Western Pacific Regional Office in Manila, where she directed regional strategies, policy development, and capacity-building initiatives for HIV and STI programmes across multiple countries.
Before joining WHO, she held several senior positions at Family Health International (FHI), including Country Director for FHI Philippines, Senior Technical Officer for Asia and the Pacific, and Director of the STI/HIV Capacity Building Grant under the Bill & Melinda Gates Foundation–supported Avahan India AIDS Initiative. In these roles, she provided strategic and technical direction for national HIV/STI programmes, managed partnerships with governments and civil society, and led large-scale capacity development initiatives to ensure the quality, standardization, and scalability of HIV/STI services for key and vulnerable populations. Over the course of her career, she has worked closely with approximately 30 national HIV/STI programmes worldwide, providing technical assistance, policy guidance, and programmatic leadership.
Dr. Wi began her career as an STI Programme Manager and Clinician with the Department of Health in the Philippines, where she managed STI services and trained other STI physicians. She also served as a Consultant for the World Bank’s Women’s Health and Safe Motherhood Project, contributing to the strengthening of reproductive and maternal health programmes in the Philippines.
Dr. Wi earned her Doctor of Medicine (MD) and Bachelor of Science in Biology degrees from Saint Louis University in the Philippines. She completed post-doctoral training in the Epidemiology of AIDS at the University of California, Los Angeles (UCLA) and specialized STI/HIV research training at the University of Washington, Seattle.
A Fellow of the Philippine Society of Venereology (FPSVI), Dr. Wi has authored and co-authored over 70 peer-reviewed scientific publications and led the development of several WHO global guidelines and technical reports. Her career reflects an enduring commitment to advancing STI and HIV research, strengthening health systems, and shaping global health policy to improve public health outcomes worldwide.
The Strategic Partnerships Committee
The Strategic Partnerships Committee is a subcommittee of the GARDP Board. It ensures that GARDP partnerships with the private sector align with GARDP’s vision, mission and objectives.
Bernard Pécoul
Chair
Independent
Yann Ferrisse
Committee Secretary
GARDP
Dominique Carouge
Committee member
Independent
Gregg Alton
Committee member
Independent
Rachel Christinat
Committee member
Independent
Guillaume Leroy
Committee member
Global Life Sciences Advisory
Jean-Pierre Paccaud
Permanent invitee
GARDP
Veronika von Messling
Committee member
Federal Ministry of Research, Technology and Space
Strategic Partnerships Committee
Bernard Pécoul
Dr Bernard Pécoul led the Drugs for Neglected Diseases initiative (DNDi) from its foundation in 2003 until 2022. Under his leadership, DNDi – a not-for-profit research and development organization – expanded to include hundreds of public and private partners on five continents. During his tenure, DNDi delivered 12 new treatments for six deadly diseases, including malaria, leishmaniasis, sleeping sickness and Chagas disease. Dr Pécoul’s work has helped to demonstrate that an alternative, collaborative model of research & development can deliver to meet the needs of neglected patients. During his time at DNDi, the organization established five research platforms that are driving scientific and medical progress in countries and communities most affected by neglected diseases. Dr Pécoul is a lifelong advocate for better access to medicines.
In 2016, DNDi, together with the World Health Organization, created GARDP to address the growing threat of antimicrobial resistance. GARDP became an independent entity in 2018.
Dr Pécoul is a recipient of the Prince Mahidol Award in the field of public health (2020) and the American Society of Tropical Medicine and Hygiene Clara Southmayd Ludlow Medal (2022).
He began his career as a Médecins Sans Frontières (MSF) doctor in 1983, working in Africa, Latin America and Asia. He later served as Executive Director of MSF France from 1991 to 1998 and as Director of the MSF Access to Essential Medicines Campaign from 1998 to 2003. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specializing in epidemiology. After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws degree by the University of Dundee, UK. Dr Pécoul was a board member of GARDP from 2019 to 2024. He is a member of the Board of the European Clinical Research Alliance on Infectious Diseases (ECRAID) and a former founding board member of UNITAID’s Medicines Patent Pool.
Strategic Partnerships Committee
Yann Ferrisse
Yann Ferrisse joined GARDP in January 2018, initially as a Business Development and Analysis Leader. Since October 2022, he has held the position of Business Development & Partner Engagement Director. In this role, he manages all interactions with private partners to enrich GARDP’s portfolio and ensure product delivery at national/regional level.
Prior to joining GARDP, Yann was Managing Director of an innovation consulting firm, focused on exploring and developing uncharted territory. He was responsible for setting up country offices in Europe and Asia (Singapore – the company’s first office in Asia and the hub of their APAC activities).
Alongside his principal role in business development, Yann has been instrumental in the creation of SECURE, an initiative to expand access to essential antibiotics, in close collaboration with WHO and with strategic input from CHAI and UNICEF.
Between 2010 and 2015, Yann was invited to join the Conseillers du Commerce Extérieur de la France, where he acted as French Foreign Trade Advisor.
Strategic Partnerships Committee
Dominique Carouge
Mr. Dominique Carouge began his career as an external auditor at Ernst & Young in France and in the United States.
Then, he joined Sanofi in 1991 where he held various financial and management positions for 29 years with increasing responsibilities in France and internationally, until he became Executive Vice-President – Business Transformation, and joined the Group’s Executive Committee in 2018.
Previously, he was Chief Financial Officer for Hoechst Marion Roussel in Australia, Head of Business Planning and Reporting at Aventis Pharma in Frankfurt and Operations Controller of the Aventis Group.
In 2005, he became Chief Financial Officer of the Vaccines Division, then Vice-President in charge of Strategy and Chief Financial Officer of Sanofi Pasteur.
In 2011, he was appointed Vice-President, Administration and Management of Sanofi Global R&D.
Then in 2016, he became Deputy Chief Financial Officer responsible for the Group’s financial operations and internal control.
Mr. Dominique Carouge is a graduate of the École Supérieure de Commerce de Reims (NEOMA). He also holds a Chartered Professional Accountant (CPA) degree and a certificate of corporate governance and non-executive director from the French Institute of Directors (IFA – Science Po).
Strategic Partnerships Committee
Gregg Alton
Mr. Alton spent more than 20 years at Gilead Sciences, where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton currently serves on the United States Presidential Advisory Council on HIV/AIDS, is a member of the board of directors of Novavax Inc., Brii Biosciences, Corcept Therapeutics, Enochian Biosciences, and several non-profit organizations, including The Hepatitis Fund, ETR and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.
Strategic Partnerships Committee
Rachel Christinat
Strategic Partnerships Committee
Guillaume Leroy
Guillaume is a seasoned international industry leader who has demonstrated a strong ability to deliver growing financial performance and public health impact.
Thanks to his passion, openness, energy and deep interest in connecting diverse people together, he successfully developed a robust track record in transforming organizations, developing talents, managing breakthrough scientific innovations, leading epidemic and pandemic responses and navigating highly complex environments. He spent 15 years in Latin America based in 4 different countries.
He is the founder and president of Global Life Sciences Advisory since 2021, advising board of directors, executive teams and International Organizations. He is CEO of EdJen Biotech and member of the board of ICW Healthcare Ventures in the USA. He also served as board member of Dillico in France.
Doctor in pharmacy with multiple executive trainings at ESCP, Wharton, INSEAD and recently MIT, he started his career at Sanofi Pasteur in Brazil, successfully launching the first Influenza vaccination program. He then took on growing P&L accountability at both country and regional levels in Africa, French Oversea Territories and finally Latin America. Under his leadership and public health focus, Sanofi Pasteur Latin America became the n° 1 leading vaccine company recognized for having set successful strategic industrial partnerships with state-owned companies in both Brazil and Mexico as well as having led the H1N1 pandemic response, providing vaccines for 20% of the whole population of Latin America.
Returning to France in 2011, he experienced the entire development of the first in class Dengue vaccine, from Phase II up to the first marketing authorization and WHO recommendation by developing a unique dedicated cross functional organization. He became CEO and President of Sanofi France with the full accountability of the commercial operations, executing the transformation roadmap of the group and representing the 25000 employees with the unions, authorities and professional organizations. He has been nominated Qualified Member of Executive Council of the MEDEF, President of different country commissions at MEDEF International and Board member of the LEEM. He ended his Sanofi experience by preparing the Global Societal Impact Strategy Roadmap of the group in 2020.
Strategic Partnerships Committee
Jean-Pierre Paccaud
Dr. Jean-Pierre Paccaud was heading the business development and corporate strategy activities of GARDP and contributed to its inception and setup.
Previously, he was heading the business development and legal teams of the Drugs for Neglected Diseases initiative (DNDi) since 2007, contributing to establish R&D partnerships with several global pharmaceutical companies as well as biotechs and academic groups. Prior to joining DNDi, Jean-Pierre founded in 2002 Athelas SA, a startup company active in the field of anti-bacterial drug discovery, which he lead until its merger with Merlion Pharmaceuticals in 2006.
Trained as a molecular and cellular biologist, Jean-Pierre earned his PhD at the University of Geneva School of Medicine and completed his post-doctoral training at UC Berkeley in the lab of Prof. Randy Schekman. Before taking on entrepreneurial challenges, Jean-Pierre spent more than 18 years in academia, working in immunology, diabetes, and cell biology, and was tenured at the University of Geneva School of Medicine. He brings to GARDP a combination of business and scientific skills, entrepreneurial experience as well as negotiation and deal-making practice in the context of global public health needs.
Strategic Partnerships Committee
Veronika von Messling
Prof. Dr. Veronika von Messling, is Director-General for Life Sciences at the German Federal Ministry of Research, Technology and Space. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.
After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.
The Nomination, Remuneration and Safeguarding Committee
The Nomination, Remuneration and Safeguarding Committee is a subcommittee of the GARDP Board. Its members are responsible for reviewing key questions about the Board itself (e.g. structure, size, and composition), reviewing organizational changes and decisions that require Board approval, and overseeing safeguarding matters (i.e. formal complaints of abuse of power or harassment).
Glenda Gray
Chair
SAMCR & Wits University
Pierre-Yves Delhez
Committee Secretary
GARDP
Chieko Ikeda
Committee member
Japanese Red Cross
Stanislas Zuin
Committee Member
Independent
The Nomination, Remuneration and Safeguarding Committee
Glenda Gray
Professor Glenda Gray is the Chief Scientific Officer at the South African Medical Research Council (SAMRC) and a Distinguished Professor and senior advisor to the Infectious Disease and Oncology Research Institute, Faculty of Health Sciences, Wits University, Johannesburg. She is also a Professor in the Vaccine and Infectious Disease Division at the Fred Hutch Cancer Research Center in Seattle. Prof Gray leads the BRILLIANT Consortium, which aims to develop an HIV vaccine pipeline emanating from the African continent. She is the former President and CEO of the SAMRC, a position she held for two five-year terms. Prof Gray also co-founded and is a non-Executive Director of the Perinatal HIV Research Unit (PHRU), in Soweto, South Africa. An A-Rated researcher, Prof Gray has been the recipient of multiple grants from the National Institutes of Health (NIH) and is internationally known for her research in HIV vaccines and interventions to prevent mother-to-child transmission of HIV.
Prof Gray’s research has focused on COVID-19 vaccine studies, paediatric treatment trials, large-scale HIV clinical trials, and TB, influenza and HPV vaccine studies in infants, children, adolescents and adults. She is co-Principal Investigator of the NIH-funded HIV Vaccine Trials Network (HVTN) and directs its programme in Africa. Prof Gray was Vice-Chair of the GARDP Board. She was also the Chair of South Africa’s Research Committee on COVID-19.
Prof Gray’s accolades over the years include the Outstanding Africa Scientist Award from the European and Developing Countries Clinical Trials Partnership, and South Africa’s highest honour, the Order of Mapungubwe, granted by the President of South Africa. She also received the N’Galy Mann Lectureship award, alongside Professor James McIntyre, at the Conference on Retroviruses and Opportunistic Infections (CROI). In recognition of her work in HIV, Forbes named Prof Gray as one of Africa’s 50 Most Powerful Women in 2020 while she was listed by The Times as one of the 100 Most Influential People in the World in 2017.
Prof Gray serves on the CEPI scientific advisory committee, has been a member of the WHO-Strategic Advisory Group for TB and has served on the World Health Organization/UNAIDS Vaccine Advisory Board, as well as the Data and Safety Monitoring Board for two vaccine studies in Africa. She chaired the standing committee on health for the Academy of Science and was appointed by South Africa’s Minister of Science, Innovation and Higher Education to the National Research Foundation and the University of Cape Town’s Council, after serving as a Member of the Wits University Council. As a member of the National Academy of Medicine, of the National Academies in the US, she served on the Board for Global Health.
The Nomination, Remuneration and Safeguarding Committee
Pierre-Yves Delhez
Pierre-Yves joined GARDP in September 2018 as Finance and Administration Director.
He is a CFO with 30 years experience in international finance and operations, growth and turnaround, controlling and compliance gained from previous roles at PriceWaterhouseCoopers and a number of US listed companies, including Eastman Kodak and Barnes Group Inc., where he was Finance Director Europe. Since moving to Switzerland in 2000, Pierre-Yves has set up the headquarters for Scitex Digital Printing and Barnes Distribution Europe and developed their international operations. In his last position before joining GARDP, Pierre-Yves worked as CFO for a privately held health care company.
A Business Administration (Ingénieur Commercial Solvay) graduate of the Université Libre de Bruxelles with a Masters in computer science, Pierre-Yves is a US Certified Public Accountant, a member of the American Institute of Certified Public Accountants, and a Chartered Global Management Accountant. He is also a graduate from the Stanford Graduate School of Business Executive Programme.
The Nomination, Remuneration and Safeguarding Committee
Chieko Ikeda
Dr Chieko Ikeda is Executive Officer of Blood Service Board of Management at the Japanese Red Cross Society. For over 30 years, she has been engaged in public health, including as Director General of the Bureau of International Health Cooperation at Japan’s National Center for Global Health and Medicine (2021-2023) and as Senior Assistant Minister for Global Health at Japan’s Ministry of Health, Labour and Welfare (2017-2019). She also previously led the technology transfer programme at the Western Pacific Regional Office of the World Health Organization (1999-2000) and worked at the UNAIDS Southeast Asia and Pacific regional office (2000-2003). Dr Ikeda has a bachelor’s degree in medicine from Tsukuba University and master’s degrees in public health and science from the Harvard School of Public Health.
The Nomination, Remuneration and Safeguarding Committee
Stanislas Zuin
Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies.
He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit.
He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).
The Audit Committee
The Audit Committee is a subcommittee of the GARDP Board. It is made up of at least two Board members as well as external auditors, and it oversees financial aspects of the organization.
Bernard Pécoul
Committee member
Independent
Pierre-Yves Delhez
Committee Secretary
GARDP
Dominique Carouge
Committee member
Independent
Stanislas Zuin
Chair
Independent
Tal Schibler
Committee member
DGE Avocats
Audit Committee
Bernard Pécoul
Dr Bernard Pécoul led the Drugs for Neglected Diseases initiative (DNDi) from its foundation in 2003 until 2022. Under his leadership, DNDi – a not-for-profit research and development organization – expanded to include hundreds of public and private partners on five continents. During his tenure, DNDi delivered 12 new treatments for six deadly diseases, including malaria, leishmaniasis, sleeping sickness and Chagas disease. Dr Pécoul’s work has helped to demonstrate that an alternative, collaborative model of research & development can deliver to meet the needs of neglected patients. During his time at DNDi, the organization established five research platforms that are driving scientific and medical progress in countries and communities most affected by neglected diseases. Dr Pécoul is a lifelong advocate for better access to medicines.
In 2016, DNDi, together with the World Health Organization, created GARDP to address the growing threat of antimicrobial resistance. GARDP became an independent entity in 2018.
Dr Pécoul is a recipient of the Prince Mahidol Award in the field of public health (2020) and the American Society of Tropical Medicine and Hygiene Clara Southmayd Ludlow Medal (2022).
He began his career as a Médecins Sans Frontières (MSF) doctor in 1983, working in Africa, Latin America and Asia. He later served as Executive Director of MSF France from 1991 to 1998 and as Director of the MSF Access to Essential Medicines Campaign from 1998 to 2003. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specializing in epidemiology. After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws degree by the University of Dundee, UK. Dr Pécoul was a board member of GARDP from 2019 to 2024. He is a member of the Board of the European Clinical Research Alliance on Infectious Diseases (ECRAID) and a former founding board member of UNITAID’s Medicines Patent Pool.
Audit Committee
Pierre-Yves Delhez
Pierre-Yves joined GARDP in September 2018 as Finance and Administration Director.
He is a CFO with 30 years experience in international finance and operations, growth and turnaround, controlling and compliance gained from previous roles at PriceWaterhouseCoopers and a number of US listed companies, including Eastman Kodak and Barnes Group Inc., where he was Finance Director Europe. Since moving to Switzerland in 2000, Pierre-Yves has set up the headquarters for Scitex Digital Printing and Barnes Distribution Europe and developed their international operations. In his last position before joining GARDP, Pierre-Yves worked as CFO for a privately held health care company.
A Business Administration (Ingénieur Commercial Solvay) graduate of the Université Libre de Bruxelles with a Masters in computer science, Pierre-Yves is a US Certified Public Accountant, a member of the American Institute of Certified Public Accountants, and a Chartered Global Management Accountant. He is also a graduate from the Stanford Graduate School of Business Executive Programme.
Audit Committee
Dominique Carouge
Mr. Dominique Carouge began his career as an external auditor at Ernst & Young in France and in the United States.
Then, he joined Sanofi in 1991 where he held various financial and management positions for 29 years with increasing responsibilities in France and internationally, until he became Executive Vice-President – Business Transformation, and joined the Group’s Executive Committee in 2018.
Previously, he was Chief Financial Officer for Hoechst Marion Roussel in Australia, Head of Business Planning and Reporting at Aventis Pharma in Frankfurt and Operations Controller of the Aventis Group.
In 2005, he became Chief Financial Officer of the Vaccines Division, then Vice-President in charge of Strategy and Chief Financial Officer of Sanofi Pasteur.
In 2011, he was appointed Vice-President, Administration and Management of Sanofi Global R&D.
Then in 2016, he became Deputy Chief Financial Officer responsible for the Group’s financial operations and internal control.
Mr. Dominique Carouge is a graduate of the École Supérieure de Commerce de Reims (NEOMA). He also holds a Chartered Professional Accountant (CPA) degree and a certificate of corporate governance and non-executive director from the French Institute of Directors (IFA – Science Po).
Audit Committee
Stanislas Zuin
Stanislas ZUIN is a certified internal auditor (CIA) and a certified fraud examiner (CFE). He holds master degrees in both economics and economic crime investigation, as well as a certificate in development studies. Throughout his career he has worked as a private banking financial analyst, a corporate finance executive, and CFO for both privately-owned and listed industrial companies.
He later founded his own consulting firm in economic crime investigation, before being elected from 2006 to 2018 as magistrate at the Court of auditors of Geneva, Switzerland. As magistrate he has managed numerous compliance and performance audits as well as fraud investigations and evaluation of public policies. He has served four years as the President of the Court and is a frequent lecturer at Universities in the fields of public finance, investigation and audit.
He currently leads its own consultancy company in the field of audit and governance, together with responsibilities as Board Vice President of Geneva International Airport, in charge of Audit & Finance committee, and as Board Member of the Geneva federation for cooperation and development (FGC).
Audit Committee